Medgenics On Target To Start Phase I/II Clinical Trials With EPODURE Protein Therapy For Anaemia Mid-2008 As Planned

Medgenics (AIM:MEDG), the US-incorporated biopharmaceutical company, is pleased to provide an update on progress towards the start of its Phase I/II clinical trials with EPODURE, its lead sustained-action protein therapy for producing and delivering erythropoietin (EPO) to treat anaemia. The Company continues to make excellent progress with its preparations to commence Phase I/II trials of EPODURE and remains confident it will begin these trials by mid-2008 as planned.

More: continued here

Filed under: Blood on April 17th, 2008